CRFA Awards 16 New Grants and Fellowships

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

ALEXANDRIA, Va--The Cancer Research Foundation of America (CRFA), a national, nonprofit organization dedicated to cancer prevention through scientific research and education, has awarded 16 new grants and fellowships totaling $528,605 for cancer prevention research. The money went to 14 institutions, most of it for 10 laboratory-based studies.

ALEXANDRIA, Va--The Cancer Research Foundation of America (CRFA), a national, nonprofit organization dedicated to cancer prevention through scientific research and education, has awarded 16 new grants and fellowships totaling $528,605 for cancer prevention research. The money went to 14 institutions, most of it for 10 laboratory-based studies.

The lone clinical trial funded--a randomized phase II chemoprevention study at the University of Colorado Health Sciences Center--will test selenium vs placebo in patients with localized prostate cancer. Drs. Karen Kelly and Nadine Mikhaeel-Kamel are the recipients.

Articles in this issue
ACS Takes Aim at Proposed Federal Tobacco Bills
Loan Defaults Disqualify 1,402
FDA Gives OK to Seven New Cancer Drugs in 1997
HIA Chemo Promising in Colon Cancer Liver Mets
Proposed Budget Spells ‘Good News’ for NCI
Proposed Budget Has Extra Funds for FDA Teen Smoking Effort
CRFA Awards 16 New Grants and Fellowships
Cancer Pain Treatment Requires Clear Terminology About ‘Addiction’
‘Staging’ of the Managed Care Market Is Crucial
NCI, EPA Attempt to Resolve Differences Over Childhood Cancer
IGF-1 Identified as Possible Risk Factor For Prostate Cancer
Radiologic Staging Tests Unwarranted In Small Breast Cancer
Immediate Reconstruction Safe After Previous Irradiation
AIDS Mortality Drops Dramatically in New York City: 1997 Data
Experts Moving Toward Consensus on Providing Access to Clinical Trials
Recent Videos
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Related Content
T-DXd demonstrated a safety profile consistent with previously reported analyses.

T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup

Tim Cortese
September 29th 2025
Article

Planned interim results from the phase 3 DESTINY-Breast05 trial showed no new safety signals with T-DXd in the trial population.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Laser vision correction. A patient and team of surgeons in the operating room during ophthalmic surgery. Eyelid speculum. Lasik treatment.| Image Credit: © romaset-stock.adobe.com

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Ariana Pelosci
September 28th 2025
Article

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.

Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL

Russ Conroy
September 26th 2025
Article

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.